Fierce BioBiotech
Agenus focuses on survival data as 0% response rate triggers primary miss
Summary
A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the study generating early evidence the cocktail improves survival, the biotechs said the data support further assessment of the combination.
A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the study generating early evidence the cocktail improves survival, the biotechs said the data support further assessment of the combination.